Published in Lancet on November 04, 2000
Oral Vitamin K for Warfarin Associated Coagulopathy | NCT00143715
Warfarin reversal. J Clin Pathol (2004) 1.33
Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol (2010) 1.00
Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ (2004) 0.97
Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. Ochsner J (2013) 0.82
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Risk Factors for Bleeding in Hospitalized Patients with Elevated INR: No Vitamin K Therapy Received Versus Vitamin K Received. Hosp Pharm (2015) 0.75
Vitamin K for warfarin-associated coagulopathy. Lancet (2001) 0.75
Warfarin Re-initiation Gone Awry: A Case of Inadvertent Overdose Mandating Critical INR Management. Can J Hosp Pharm (2015) 0.75
Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol (2009) 0.75
Vitamin K in anticoagulation therapy. Lancet (2001) 0.75
Vitamin K in anticoagulation therapy. Lancet (2001) 0.75
Vitamin K in anticoagulation therapy. Lancet (2001) 0.75
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
The Children's Depression, Inventory (CDI). Psychopharmacol Bull (1985) 11.73
Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol (1979) 8.44
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol (1991) 6.55
Rating scales to assess depression in school-aged children. Acta Paedopsychiatr (1981) 6.19
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Management of anticoagulation before and after elective surgery. N Engl J Med (1997) 5.10
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
The Drosophila ninaE gene encodes an opsin. Cell (1985) 3.65
Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry (1985) 3.57
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med (1993) 3.40
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol (1998) 3.25
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
The cloned dopa decarboxylase gene is developmentally regulated when reintegrated into the Drosophila genome. Cell (1983) 3.08
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Classification of suicidal behaviors: I. Quantifying intent and medical lethality. Am J Psychiatry (1975) 2.89
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation (1996) 2.69
Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol (1987) 2.65
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med (1972) 2.60
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Counting diabetes in the next millennium. Application of capture-recapture technology. Diabetes Care (1993) 2.33
Establishing a therapeutic range for heparin therapy. Ann Intern Med (1993) 2.31
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Rous sarcoma virus p19 binds to specific double-stranded regions of viral RNA: effect of p19 on cleavage of viral RNA by RNase III. Virology (1978) 2.26
Managing oral anticoagulant therapy. Chest (2001) 2.25
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med (1992) 2.23
Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med (1973) 2.17
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost (2015) 2.07
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation (2004) 2.05
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med (1981) 2.04
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Epidural analgesia for pain relief following hip or knee replacement. Cochrane Database Syst Rev (2003) 1.96
Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol (1966) 1.94
Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med (2001) 1.93
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol (2000) 1.92
Requirement of circadian genes for cocaine sensitization in Drosophila. Science (1999) 1.92
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest (1985) 1.92
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br (2009) 1.91
Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol (2000) 1.90
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation (1995) 1.90
Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet (1970) 1.84
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81